We transiently and stably knocked down LY6K in the LY6K-positive breast cancer cell lines, MCF7-ADR and mouse adapted MDA-MB-231 cells (MB-231/A), using siRNA and lentivirus, respectively. This evidence concerns the gene LY6K and breast cancer.